Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 308

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 308
---
 common stock issuable upon the exercise of options held by Mr. Sawhney that are 
 exercisable within 60 days of June 30, 2025.                                                          |

| (7) | Consists of (i) 100,000 shares of common stock and (ii) 426,038 shares of common stock issuable upon the 
 exercise of options held by Dr. Eramo that are exercisable within 60 days of June 30, 2025.              |

| (8) | Consists of shares of common stock issuable upon the exercise of options held by Mr. Garland that are 
 exercisable within 60 days of June 30, 2025.                                                          |

| (9) | Consists of (i) 66,000 shares of common stock and (ii) 176,249 shares of common stock issuable upon the 
 exercise of options held by Dr. Ruffolo that are exercisable within 60 days of June 30, 2025.           |

| (10) | Consists of (i) 2,454,012 shares of common stock beneficially owned by our current executive officers and                                                                                                                                        
 directors and (ii) 33,347,081 shares of common stock issuable up on conversion of shares of our redeemable convertible preferred stock, (iii) warrants to purchase up to 6,874 shares of common stock, and (iv) 2,096,447 shares of common stock 
 issuable upon common stock issuable upon the exercise of options held by our current executive officers and directors within 60 days of June 30, 2025.                                                                                           |

210

DESCRIPTION OF CAPITAL STOCK

The following description of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and
restated bylaws, as each will become effective immediately prior to the closing of this offering, are summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated bylaws, which are
filed as exhibits to the registration statement of which this prospectus is part.

General

Upon the closing of this offering, our authorized capital stock will consist of shares of common stock, par value
$0.0001 per share, and shares of preferred stock, par value $0.0001 per share. All of our authorized preferred stock upon the completion of this offering will be undesignated.

As of June 30, 2025, after giving effect